Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.12
Tweet Send to a FriendGet Alerts NABI Hot Sheet
Price: $1.80 --0%
Revenue Growth %: -42.5%
Financial Fact:
Research and development expenses: 4.94M
Today's EPS Names:
ANF, DXLG, FL, More
Revenue Growth %: -42.5%
Financial Fact:
Research and development expenses: 4.94M
Today's EPS Names:
ANF, DXLG, FL, More
Trade NABI Now!
Nabi Biopharmaceuticals (NASDAQ: NABI) reported Q3 EPS of ($0.12), versus ($0.07) reported last year. Revenue for the quarter came in at $632 thousand, versus $1.1 million reported last year.
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Nabi Biopharmaceuticals (NABI) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 6c as Sales Slide 10%
- Shoe Carnival, Inc. (SCVL) Tops Q1 EPS by 6c, Guides Q2 In-Line
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
